Published Research and Presentations

Abstract 6: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).

TheraP

ASCO GU 2021 - Virtual Meeting

11/02/2021

Michael S Hofman, FRACP, MBBS

TheraP: A randomised phase 2 trial of Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel – initial results (ANZUP protocol 1603)

TheraP

ASCO 2020 - Virtual Meeting

29/05/2020

Hofman, M et al.

Abstract TPS768: UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.

UNISoN

ASCO GU 2020

13/02/2020

Craig Gedye, PhD, FRACP

Abstract TPS602: Adding mitomycin to Bacillus Calmette-Guérin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301)

BCG+MM

ASCO GU 2020

13/02/2020

Elizabeth Liow, MBBS, FRACP

Abstract TPS425: P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)

P3BEP

ASCO GU 2020

13/02/2020

Shalini Subramaniam, MBBS

Abstract 485: Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)

PCR MIB

ASCO GU 13-15 February 2020

13/02/2020

Andrew Weickhardt, FRACP, MBBS

Abstract TPS385: DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer

DASL-HiCaP

ASCO GU 2021 - Virtual Meeting

13/02/2020

Tamim Niazi, MD

Health-related quality of life (HRQL) in a randomized phase 3 trial of enzalutamide with standard first line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial.

ENZAMET

ESMO 2019 Congress Poster Discussion

29/09/2019

Professor Martin Stockler

Primary Efficacy Analysis Results From The SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: an international, randomised double blind phase III trial led by the MRC CTU at UCL.

SORCE

ESMO 2019 Congress

28/09/2019

Professor Tim Eisen on behalf of the SORCE Trial Management Group

Overall survival (OS) Results of a Phase III Randomized Trial of Standard of Care Therapy with or without enzalutamide for a Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP –led International Co-operative Group Trial

ENZAMET

MOGA ASM

16/08/2019

Professor Ian D. Davies